Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $537.74, for a total transaction of $5,108,530.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $21,785,460.62. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Price Performance

Shares of UTHR opened at $543.39 on Friday. The stock has a 50-day moving average of $561.93 and a 200-day moving average of $525.46. The company has a market cap of $23.07 billion, a PE ratio of 20.06, a P/E/G ratio of 1.81 and a beta of 0.57. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted $6.63 earnings per share. Analysts expect that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at $31,000. International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on UTHR shares. UBS Group upped their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.